The addition of programmed cell death protein 1 (PD-1) immune checkpoint inhibitors (ICIs) to chemotherapy in patients with stage III-IV SMARCA4-deficient NSCLC resulted in better one-year survival and progression-free survival in a small study from China [30]. Here, SMARCA4 is linked to non-small cell lung carcinoma.